Journal
ACS NANO
Volume 9, Issue 7, Pages 6985-6995Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.5b01324
Keywords
nanomedicine; cancer; EPR-effect; drug delivery; imaging; nanoparticles; liposomes
Categories
Funding
- Danish Strategic Research Council (NABIIT) [2106-07-0033]
- Lundbeck Foundation
- European Research Council (ERC)
- Lundbeck Foundation [R105-2011-9829] Funding Source: researchfish
- Novo Nordisk Fonden [NNF13OC0007149, NNF14SA0011693] Funding Source: researchfish
- The Danish Cancer Society [R72-A4569] Funding Source: researchfish
Ask authors/readers for more resources
Since the first report of the enhanced permeability and retention (EPR) effect, the research in nanocarrier based antitumor drugs has been intense. The field has been devoted to treatment of cancer by exploiting EPR-based accumulation of nanocarriers in solid tumors, which for many years was considered to be a ubiquitous phenomenon. However, the understanding of differences in the EPR-effect between tumor types, heterogeneities within each patient group, and dependency on tumor development stage in humans is sparse. It is therefore important to enhance our understanding of the [PR-effect in large animals and humans with spontaneously developed cancer. In the present paper, we describe a novel loading method of copper-64 into PEGylated liposomes and use these liposomes to evaluate the EPR-effect in 11 canine cancer patients with spontaneous solid tumors by PET/CT imaging. We thereby provide the first high-resolution analysis of EPR-based tumor accumulation in large animals. We find that the EPR-effect is strong in some tumor types but cannot be considered a general feature of solid malignant tumors since we observed a high degree of accumulation heterogeneity between tumors. Six of seven included carcinomas displayed high uptake levels of liposomes, whereas one of four sarcomas displayed signs of liposome retention. We conclude that nanocarrier-radiotracers could be important in identifying cancer patients that will benefit from nanocarrier-based therapeutics in clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available